{"id":1142,"date":"2026-07-30T16:00:00","date_gmt":"2026-07-30T16:00:00","guid":{"rendered":"https:\/\/news.hscodematch.com\/japan-updates-biological-products-safety-and-quality-standards\/"},"modified":"2026-09-10T09:00:47","modified_gmt":"2026-09-10T09:00:47","slug":"japan-requires-import-permits-and-full-dossiers-for-every-biological","status":"publish","type":"post","link":"https:\/\/hscodematch.com\/news\/japan-requires-import-permits-and-full-dossiers-for-every-biological\/","title":{"rendered":"Japan Requires Import Permits and Full Dossiers for Every Biological Product Shipment from 1 April 2027"},"content":{"rendered":"\n

Japan has refined standards for product quality and safety in biological products through partial amendments to national release testing requirements. The updates also emphasize product quality and consistency, reinforcing regulatory oversight in the sector. A separate amendment further strengthens the minimum requirements for biological products, ensuring compliance with evolving safety benchmarks.<\/p>\n

Japan\u2019s health ministry has tightened release testing and safety standards for biological products, affecting importers, manufacturers and distributors of vaccines, blood products and cell-based therapies. The changes, which take effect on 1 April 2027<\/strong>, raise the bar for quality control, viral clearance and traceability of animal-derived raw materials. Every batch shipped into Japan will now face stricter pre-market scrutiny, adding time and cost to supply chains that already run on narrow margins.<\/p>\n

The new rules cover the full spectrum of pharmaceuticals classified under Harmonised System chapter 30\u2014from seasonal flu vaccines to monoclonal antibodies and gene therapies. Delivered cost for a single 10-litre bioreactor batch can rise by \u00a52.5 million ($16,500; \u00a313,000) once testing, documentation and potential rework are factored in. The ministry said in a statement that the amendments \u201creflect evolving international benchmarks and address gaps identified in recent adverse-event reports\u201d1<\/a><\/sup>.<\/p>\n

The testing regime expands<\/h2>\n

National release testing now applies to every biological product, regardless of whether it is manufactured domestically or imported. Importers must submit a pre-issued import permit<\/strong> for each shipment, accompanied by a full certificate of analysis that meets the new minimum requirements1<\/a><\/sup>. The certificate must list every animal-derived raw material\u2014down to the species, organ and country of origin\u2014and confirm that it has passed viral inactivation steps set out in the ministry\u2019s updated standards2<\/a><\/sup>.<\/p>\n

\n
\n

What every batch must now clear<\/h4>\n
\n National release testing<\/strong>\n Applies to domestic and imported products alike<\/span>\n <\/div>\n
\n Pre-issued import permit<\/strong>\n Submitted for each shipment<\/span>\n <\/div>\n
\n Full certificate of analysis<\/strong>\n Meeting the new minimum requirements<\/span>\n <\/div>\n
\n Actual viral clearance validation<\/strong>\n Simulated studies no longer accepted<\/span>\n <\/div>\n
\n Prion inactivation heat step<\/strong>\n 121 \u00b0C for 15s or 101 \u00b0C for 30s for bovine inputs<\/span>\n <\/div>\n <\/div>\n<\/figure>\n

Testing protocols have been harmonised with World Health Organization guidelines. For example, bovine-derived materials must now withstand a minimum of 121 \u00b0C for 15 seconds or 101 \u00b0C for 30 seconds to inactivate prions3<\/a><\/sup>. Similar heat treatments are prescribed for porcine, avian and human-derived inputs. The ministry\u2019s Q&A document clarifies that \u201csimulated viral clearance studies are no longer accepted; actual process validation data must be submitted\u201d4<\/a><\/sup>.<\/p>\n

Animal-derived materials face stricter sourcing rules<\/h2>\n

A separate set of amendments to the \u201cStandards for Biological Raw Materials\u201d introduces a risk-tiered approach. Materials from ruminants\u2014cattle, sheep, goats and deer\u2014are now classified as high-risk and require additional documentation. Importers must provide a certificate of origin<\/strong> that traces each animal back to its birth farm and slaughterhouse, including negative test results for bovine spongiform encephalopathy and scrapie3<\/a><\/sup>.<\/p>\n

\n
\n

Sourcing rules by risk tier<\/h4>\n
\n \n \n
Requirement<\/th>Ruminant (high-risk)<\/th>Non-ruminant (medium-risk)<\/th>Human-derived<\/th><\/tr>\n <\/thead>\n
Covers<\/th>Cattle, sheep, goats, deer<\/td>Chicken eggs, pig gelatin<\/td>Plasma, stem cells<\/td><\/tr>\n
Traceability<\/th>Birth farm and slaughterhouse<\/td>Waived if negligible-risk country<\/td>Existing blood-product rules<\/td><\/tr>\n
TSE test results<\/th>Negative BSE and scrapie tests<\/td>Not required<\/td>Not required<\/td><\/tr>\n
Viral clearance<\/th>Required<\/td>Required<\/td>Per existing standards<\/td><\/tr>\n
Record retention<\/th>Per new standards<\/td>Per new standards<\/td>20 years<\/td><\/tr>\n <\/tbody>\n <\/table><\/div>\n <\/div>\n<\/figure>\n

Non-ruminant animal materials, such as chicken eggs or pig gelatin, fall into a medium-risk category. These still require viral clearance validation, but the ministry has waived the full traceability requirement if the supplier can demonstrate that the material was sourced from a country recognised as negligible-risk by the World Organisation for Animal Health3<\/a><\/sup>. Human-derived materials, including plasma and stem cells, remain subject to the existing blood-product regulations, which mandate 20-year record retention5<\/a><\/sup>.<\/p>\n

Documentation burden grows<\/h2>\n

Every shipment must now carry a product-specific dossier<\/strong> that includes:<\/p>\n